F11 and hemorrhagic disease: From a clinical perspective, the findings underscore the value of early TXA administration in women with diagnosed bleeding disorders, particularly those with VWD and FXI deficiency, where factor levels may either fail to rise during pregnancy or decline precipitously after childbirth.